Autonomous Sandoz Set To Be Tighter And Leaner

 
• By Aidan Fry

With an optimized manufacturing base, a narrower geographic footprint, and a tighter portfolio focus on differentiated biosimilars and hard-to-make generics, Novartis believes a more autonomous Sandoz division can remain an “integral part” of the Swiss group.

Performance
A tighter and leaner operating focus is intended to raise profit margins at Sandoz • Source: Shutterstock

More from Biosimilars

More from Products